Fernanda Raquel Da Silva Andrade Researcher at Drug Delivery and Targeting Group - Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain, and is an Associate Professor in the Department of Pharmaceutical Technology from the Faculty of Pharmacy and Food Science from University of Barcelona, Spain. Has a Master in Pharmaceutical Sciences (University of Lisbon, Portugal) and a PhD degree in Pharmaceutical Sciences - Pharmaceutical Technology (University of Porto, Portugal). Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Email Fernanda Raquel Da Silva Andrade Email Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Researcher at Drug Delivery and Targeting Group - Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain, and is an Associate Professor in the Department of Pharmaceutical Technology from the Faculty of Pharmacy and Food Science from University of Barcelona, Spain. Has a Master in Pharmaceutical Sciences (University of Lisbon, Portugal) and a PhD degree in Pharmaceutical Sciences - Pharmaceutical Technology (University of Porto, Portugal).
Her research interests are based on the development of formulations, namely nanoparticles, for the administration of drugs and biopharmaceuticals (peptides, proteins and genetic material) for the treatment of challenging diseases. Also has experience on study the effects of drugs and delivery systems on cancer stem cells and on the development and use of cell-culture models, animal models, and ex vivo models for drug absorption studies through the pulmonary, intestinal, and blood brain barrier. Her major objective relies on the development of multifunctional drug delivery systems with improved characteristics such as increased therapeutic index and targeted delivery, allowing and efficient and safe treatment of challenging diseases like cancer or infectious diseases, with the ultimate goal of personalized medicine. Her research work at different projects and collaborations with a variety of research groups from different countries have resulted in the authorship of two patents, several research and review papers, as well as book chapters.
Research lines Disseny, síntesi i caracterització de nanosistemes terapèutics biodegradables IP: Fernanda Raquel Da Silva Andrade Projects MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small Cell Lung Cancer IP: Ibane Abasolo Olaortua Collaborators: Joaquin Seras Franzoso, Fernanda Raquel Da Silva Andrade Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 333099 Reference: CPP2022-009780 Duration: 01/07/2023 - 30/06/2026 TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas IP: Begoña Benito Villabriga Collaborators: Carmen Escudero Iriarte, Ventura i Expósito, Laia, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Bou Teen, Diana, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala Funding agency: Instituto de Salud Carlos III Funding: 2494527.53 Reference: FORT23/00034 Duration: 01/01/2024 - 31/12/2027 Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT) IP: Ibane Abasolo Olaortua Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 60000 Reference: 2021 SGR 01173 Duration: 01/01/2022 - 30/06/2025 Design of Nanoparticles for Blood-Brain-Barrier Crossing and Glioblastoma Multiforme Cancer Stem Cells Targeting (NanoGlio) IP: Ibane Abasolo Olaortua Collaborators: Fernanda Raquel Da Silva Andrade, Miriam Izquierdo Sans Funding agency: Asociación Española Contra el Cáncer Funding: 100000 Reference: INVES211530DASI Duration: 01/09/2021 - 31/08/2025 Pagination Current page 1 Page 2 Next page › Last page »
